Klotho Neurosciences Stock (NASDAQ:KLTO)


OwnershipChart

Previous Close

$0.41

52W Range

$0.11 - $3.91

50D Avg

$0.34

200D Avg

$0.63

Market Cap

$20.08M

Avg Vol (3M)

$3.23M

Beta

2.23

Div Yield

-

KLTO Company Profile


Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Apr 29, 2022

Website

KLTO Performance


Peer Comparison


TickerCompany
XCURExicure, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
MTVAMetaVia Inc.
RLYBRallybio Corporation
NRSNNeuroSense Therapeutics Ltd.
NERVMinerva Neurosciences, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
SONNSonnet BioTherapeutics Holdings, Inc.